SCHEMBL4830893

SCHEMBL4830893

O=C(Cc1cccc(Cl)c1Cl)c1c[nH]c2ncccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 1/20 0.51
CCNE1 P24864 8/20 0.47
CDK2 P24941 8/20 0.47
MTNR1A P48039 1/20 0.46
GPR84 Q9NQS5 1/20 0.44
ADORA2A P29274 1/20 0.44
PKM P14618 1/20 0.43
CNR2 P34972 1/20 0.43
P2RX7 Q99572 2/20 0.42
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4831413 0.81 MAP2K1 (0.50) MAP2K1CCNE1CDK2MTNR1AGPR84
SCHEMBL14002360 0.81 MAP2K1 (0.53) MAP2K1CCNE1CDK2MTNR1AGPR84
SCHEMBL3886913 0.80 MAP2K1 (0.63) MAP2K1CCNE1CDK2MTNR1AGPR84
SCHEMBL4829499 0.78 ADORA2A (0.61) MAP2K1CCNE1CDK2MTNR1AGPR84
SCHEMBL415380 0.78 MAP2K1 (0.57) MAP2K1CCNE1CDK2GPR84ADORA2A
SCHEMBL4831662 0.76 MAP2K1 (0.56) MAP2K1CCNE1CDK2MTNR1AGPR84
SCHEMBL4466016 0.76 MAP2K1 (0.61) MAP2K1CCNE1CDK2MTNR1AGPR84
SCHEMBL12729266 0.76 MAP2K1 (0.66) MAP2K1CCNE1CDK2MTNR1AGPR84
SCHEMBL13306576 0.76 MAP2K1 (0.61) MAP2K1CCNE1CDK2MTNR1AGPR84
SCHEMBL13333283 0.76 MAP2K1 (0.61) MAP2K1CCNE1CDK2MTNR1AGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-20050137201-A1 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137201-A1 Compositions useful as inhibitors of protein kinases MAP3K20, PACSIN2, MAP3K6 MAP2K1 403/4885CCNE1 1053/4885CDK2 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.